<DOC>
	<DOCNO>NCT00680901</DOCNO>
	<brief_summary>This international multi-center trial enroll patient locally advance , unresectable , metastatic gastric , esophageal , gastro-esophageal junction cancer whose tumor amplification ErbB2 ( HER2 ) gene . The trial investigate whether lapatinib , add chemotherapy regimen , capecitabine plus oxaliplatin ( CapeOx ) , extend time progression overall survival . Tumor ErbB2 ( HER2 ) status must know trial entry . CapeOx administer patient , patient randomly assign receive either lapatinib placebo .</brief_summary>
	<brief_title>LOGiC - Lapatinib Optimization Study ErbB2 ( HER2 ) Positive Gastric Cancer : A Phase III Global , Blinded Study Designed Evaluate Clinical Endpoints Safety Chemotherapy Plus Lapatinib</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Signed informed consent ; Histologically confirm gastric , esophageal , gastroesophageal junction adenocarcinoma ; disease locally advanced ( unresectable ) , metastatic , locally recurrent disease ; Measurable nonmeasurable , radiologically evaluable disease , accord RECIST ; ErbB2 ( HER2 ) positive ; Age =18 year ; ECOG Performance status = 2 ; Adequate organ function , include adequate hematologic , renal liver function ; Cardiac ejection fraction within institutional range normal measure echocardiogram ; Able swallow retain oral medication , and/or receive enteral medication via gastrectomy feed tube ; Women men potential child must willing practice acceptable method birth control study ; Prior gastric surgery permit &gt; 3 week prior recover ; Prior chemotherapy nongastric malignancy &gt; 5 year ; Prior neoadjuvant and/or adjuvant chemotherapy early stage gastric cancer &gt; 6 month since completion ; At least 4 week since prior radiotherapy ; Prior biologic , hormonal , immunologic cancer treatment &gt; 5 year since treatment . Pregnant lactating female ; Known history active CNS disease ; Uncontrolled ascites ; Concurrent anticancer therapy ; Gastric carcinoid , epidermoid , sarcoma , squamous cell carcinoma ; Prior palliative chemotherapy treatment gastric cancer ; Prior treatment oxaliplatin &lt; 12 month ; Malabsorption syndrome uncontrolled inflammatory gastrointestinal disease ; Known history uncontrolled symptomatic angina , arrhythmia , congestive heart failure ; Preexisting grade = 2 motor sensory neuropathy ; Uncontrolled infection ; Concurrent disease condition would make subject inappropriate study participation serious medical condition would interfere subject '' safety ; Active hepatic biliary disease ; History malignancy except diseasefree 5 year , history completely resect nonmelanoma skin cancer , successfully treat situ carcinoma ; Unresolved unstable serious toxicity prior administration another investigational drug and/or prior cancer treatment ; Dementia , alter mental status , psychiatric condition would prohibit understanding rendering informed consent ; Known history DPD deficiency ; Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate lapatinib , capecitabine , fluorouracil , platins excipients ; Use investigational drug within 30 day prior randomization ; Use concurrent prohibit medication would interact study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>unresectable</keyword>
	<keyword>HER2</keyword>
	<keyword>TYVERB</keyword>
	<keyword>ErbB2</keyword>
	<keyword>TYKERB</keyword>
	<keyword>capecitabine</keyword>
	<keyword>CapeOx</keyword>
	<keyword>gastric/esophageal cancer</keyword>
	<keyword>GE junction</keyword>
	<keyword>metastatic</keyword>
	<keyword>lapatinib</keyword>
	<keyword>oxaliplatin</keyword>
</DOC>